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Jari Sjöberg4, Ralf Bützow3, Nanna Sarvilinna1,2,4,5, Hanna-Riikka Heinonen1,2,
Jaana Tolvanen1,2, Simona Bramante1,2, Tomas Tanskanen1,2, Juha Auvinen6,7,
Outi Uimari8, Amjad Alkodsi1,2, Rainer Lehtonen1,2, Eevi Kaasinen1,2,9,
Kimmo Palin1,2, Lauri A Aaltonen1,2*
1Department of Medical and Clinical Genetics, University of Helsinki, Helsinki,
Finland; 2Genome-Scale Biology Research Program, Research Programs Unit,
University of Helsinki, Helsinki, Finland; 3Department of Pathology, University of
Helsinki and Helsinki University Hospital, Helsinki, Finland; 4Department of
Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital,
Helsinki, Finland; 5Institute of Biomedicine, Biochemistry and Developmental
Biology, University of Helsinki, Helsinki, Finland; 6Northern Finland Birth Cohorts’
Project Center, Faculty of Medicine, University of Oulu, Oulu, Finland; 7Center for
Life Course Health Research, Faculty of Medicine, University of Oulu, Oulu, Finland;
8Department of Obstetrics and Gynecology, PEDEGO Research Unit, Medical
Research Center Oulu, Oulu University Hospital, University of Oulu, Oulu, Finland;
9Division of Functional Genomics and Systems Biology, Department of Medical
Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
Abstract Uterine leiomyomas (ULs) are benign tumors that are a major burden to women’s
health. A genome-wide association study on 15,453 UL cases and 392,628 controls was performed,
followed by replication of the genomic risk in six cohorts. Effects of the risk alleles were evaluated
in view of molecular and clinical characteristics. 22 loci displayed a genome-wide significant
association. The likely predisposition genes could be grouped to two biological processes. Genes
involved in genome stability were represented by TERT, TERC, OBFC1 - highlighting the role of
telomere maintenance - TP53 and ATM. Genes involved in genitourinary development, WNT4,
WT1, SALL1, MED12, ESR1, GREB1, FOXO1, DMRT1 and uterine stem cell marker antigen CD44,
formed another strong subgroup. The combined risk contributed by the 22 loci was associated with
MED12 mutation-positive tumors. The findings link genes for uterine development and genetic




Uterine leiomyomas (ULs), also known as fibroids or myomas, are benign smooth muscle tumors of
the uterine wall. They are extremely common; approximately 70% of women develop ULs before
menopause (Stewart et al., 2017). The symptoms, occurring in one fifth of women, include
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excessive menstrual bleeding, abdominal pain and pregnancy complications (Stewart et al., 2017).
In most cases, durable treatment options are invasive (Stewart, 2015). ULs cause a substantial
human and economic burden, and the annual cost of treating these tumors has been approximated
to be as high as $34 billion in the United States, higher than the combined cost of treating breast
and colon cancer (Cardozo et al., 2012).
Earlier studies have indicated strong genetic influence in UL susceptibility based on linkage
(Gross, 2000), population disparity (Wise et al., 2012) and twin studies (Luoto et al., 2000). The
most striking UL predisposing condition thus far characterized is hereditary leiomyomatosis and
renal cell cancer (HLRCC) syndrome, caused by high-penetrance germline mutations in the Fumarate
hydratase (FH) gene (Multiple Leiomyoma Consortium et al., 2002; Launonen et al., 2001).
Genome-wide association studies (GWAS) have proposed several low-penetrance risk loci but few
unambiguous predisposing genes have emerged. Cha et al. reported loci in chromosome regions
10q24.33, 11p15.5 and 22q13.1 based on a Japanese patient cohort (Cha et al., 2011). The 11p15.5
locus - near the Bet1 golgi vesicular membrane trafficking protein like (BET1L) gene - was later repli-
cated in Caucasian ancestry (Edwards et al., 2013a). The 22q13.1 locus has been replicated in Cau-
casian, American and Saudi Arabian populations suggesting trinucleotide repeat containing 6B
(TNRC6B) as a possible target gene (Edwards et al., 2013a; Aissani et al., 2015; Bondagji et al.,
2017). Further UL predisposition loci have been suggested at 1q42.2 and 2q32.2 by Zhang et al
(Zhang et al., 2015). and, at 3p21.31, 10p11.21 and 17q25.3 by Eggert et al (Eggert et al., 2012).
A recent work reported cytohesin 4 (CYTH4) at 22q13.1 as a novel candidate locus in African ances-
try (Hellwege et al., 2017). While multiple loci and genes have been implicated through these valu-
able studies it is not straightforward to connect any of them mechanistically to UL development.
Most ULs show somatic site-specific mutations at exons 1 and 2 of the mediator complex subunit
12 (MED12) gene (Mäkinen et al., 2011; Heinonen et al., 2014). These observations together with
further scrutiny of driver mutations, chromosomal aberrations, gene expression, and clinicopatholog-
ical characteristics have led to identification of at least three mutually exclusive UL subtypes; MED12
mutant, Fumarate Hydratase (FH) deficient, as well as High Mobility Group AT-Hook 2 (HMGA2)
overexpressing lesions (Mehine et al., 2016).
eLife digest Fibroids – also known as uterine leiomyomas, or myomas – are a very common
form of benign tumor that grows in the muscle wall of the uterus. As many as 70% of women
develop fibroids in their lifetime. About a fifth of women report symptoms including severe pain,
heavy bleeding during periods and complications in pregnancy. In the United States, the cost of
treating fibroids is estimated to be $34 billion each year.
Despite the prevalence of fibroids in women, there are few treatments available. Drugs to target
them have limited effect and often an invasive procedure such as surgery is needed to remove the
tumors. However, a better understanding of the genetics of fibroids could lead to a way to develop
better treatment options.
Välimäki, Kuisma et al. used a genome-wide association study to seek out DNA variations that are
more common in people with fibroids. Using data from the UK Biobank, the genomes of over
15,000 women with fibroids were analyzed against a control population of over 392,000 individuals.
The analysis revealed 22 regions of the genome that were associated with fibroids. These regions
included genes that may well contribute to fibroid development, such as the gene TP53, which
influences the stability of the genome, and ESR1, which codes for a receptor for estrogen – a
hormone known to play a role in the growth of fibroids. Variation in a set of genes known to control
development of the female reproductive organs was also identified in women with fibroids.
The findings are the result of the largest genome-wide association study on fibroids, revealing a
set of genes that could influence the development of fibroids. Studying these genes could lead to
more effective drug development to treat fibroids. Revealing this group of genes could also help to
identify women at high risk of developing fibroids and help to prevent or manage the condition.
DOI: https://doi.org/10.7554/eLife.37110.002
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Here we report the most powerful GWAS on uterine leiomyoma to date, and novel genome-wide
significant UL susceptibility loci with plausible adjacent predisposition genes. These genes associate
UL genesis to two distinct biological mechanisms: Genome stability related processes are implicated
by genes Tumor Protein P53 (TP53) and ATM Serine/Threonine Kinase (ATM) together with the telo-
mere maintenance genes Telomerase Reverse Transcriptase (TERT), Telomerase RNA Component
(TERC) and STN1-CST Complex Subunit (OBFC1). The other prominent group is genes relevant for
genitourinary development, specifically Wnt Family Member 4 (WNT4), Wilms Tumor 1 (WT1), Spalt
Like Transcription Factor 1 (SALL1), Estrogen Receptor 1 (ESR1 or ERa), Growth Regulation By Estro-
gen In Breast Cancer 1 (GREB1), Forkhead Box O1 (FOXO1), Doublesex and Mab-3 Related Tran-
scription Factor 1 (DMRT1) and CD44 Molecule (CD44). Our analysis of the X chromosome identifies
a risk allele near MED12 that drives UL tumorigenesis towards somatic MED12 mutations. We report
altogether 22 genome-wide significant susceptibility loci and compile them into a polygenic risk
score. The UL association is then replicated in six independent cohorts of different ethnic origins:
individuals of African origin are characterized by the highest risk load. Finally, we investigate the risk
alleles’ association to clinical features, molecular UL subtypes, telomere length, gene expression and
DNA methylation.
Figure 1. Outline of the study stages and genotyping cohorts. GRS, genomic risk score. NFBC, Northern Finland Birth Cohort.
DOI: https://doi.org/10.7554/eLife.37110.003
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Results
Identification of predisposition loci
Figure 1 provides an outline of this study. At discovery stage 1,428 SNPs emerging from 22 distinct
genetic loci passed the genome-wide significance level of 5  10 8. Figure 2 displays a Manhattan
plot of these associations (15,453 UL cases and 392,628 controls; linear mixed model). Two of the
Figure 2. Overview of the uterine leiomyoma risk loci and the effect of increased number of MED12-mutated lesions per rs5937008 risk allele. (A),
Manhattan plot of the UK Biobank GWAS on 15,453 UL cases and 392,628 controls. On Y-axis, logarithm transformed association values, and on X-axis,
autosomes and the X chromosome. The blue horizontal line denotes genome-wide significance (p=5  10 8). Gene symbols shown for reference. (B),
MED12 region in more detail. ENCODE tracks (details in Supplementary Methods) are shown for reference. (C), The risk allele near MED12 (rs5937008)
is observed with a significant increase in number of MED12-mutation-positive tumors (p=0.009; negative binomial regression; RR = 1.23 per risk allele;
n = 457 Helsinki cohort patients).
DOI: https://doi.org/10.7554/eLife.37110.004
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significant loci (359/1,428 SNPs) were found on the X chromosome. After linkage disequilibrium (LD;
r2 0.3) pruning the significant SNPs, a total of 50 LD-independent associations remained: the result-
ing SNPs are given in Appendix 1—table 2, and the lead SNPs are summarized in Table 1.
Appendix 1—figure 1 displays the regional structure of each locus together with flanking associ-
ation values, linkage disequilibrium (LD) and genome annotation. Annotation tracks are included for
tissue-specific data on open chromatin, topologically associating domains (TAD) and other regula-
tory features (details in Supplementary Methods).
Genomic risk score
A polygenic risk score (Abraham and Inouye, 2015) was compiled based on the discovery stage
associations. After LD pruning (r2 0.3) the discovery-stage SNPs, 50 SNPs from the 22 distinct loci
passed for the initial genomic risk score (GRS; Appendix 1—table 4). The SNP weights were based
on UKBB log-odds. We applied this initial GRS of 50 SNPs to the Helsinki cohort and identified a sig-
nificant association to the UL phenotype (p=8.3  10 10; adjusted p=1.1  10 8; one-tailed Wil-
coxon rank-sum; W = 1.69  106; 457 cases and 8899 female controls).
Meta-analysis
The second stage GWAS combined the UKBB and Helsinki cohorts for a meta-analysis approach.
The genome-wide statistics revealed rs117245733, at 13q14.11, as the only SNP with a suggestive
Table 1. Predisposition loci for uterine leiomyoma.
Chr Position rs-code A B B freq OR P Likely disease gene
6 152,562,271 rs58415480 C G 0.155 1.18 6.0E-29 ESR1
X 131,312,089 rs5930554 T C 0.311 1.14 4.3E-25 ?
17 7,571,752 rs78378222 # T G 0.013 1.53 9.7E-25 TP53
11 32,370,380 rs10835889 G A 0.159 1.14 5.5E-19 WT1
11 108,149,207 rs141379009 T G 0.027 1.32 2.0E-18 ATM
9 802,228 rs7027685 A T 0.402 1.11 3.8E-18 DMRT1
1 22,450,487 rs2235529 # C T 0.157 1.14 1.1E-17 WNT4/CDC42
X 70,093,038 rs5937008 C T 0.520 0.91 5.6E-16 MED12
5 1,283,755 rs72709458 # C T 0.206 1.12 6.9E-16 TERT
11 225,196 rs507139 * G A 0.074 0.84 3.2E-13 ?
4 54,546,192 rs62323680 G A 0.067 1.16 8.3E-13 ?
3 169,514,585 rs10936600 # A T 0.244 0.91 6.4E-12 TERC
13 41,179,798 rs7986407 A G 0.310 1.09 1.2E-11 FOXO1
3 197,623,337 rs143835293 A G 0.002 1.75 1.8E-11 ?
12 46,831,129 rs12832777 T C 0.701 1.09 2.3E-11 ?
22 40,669,648 rs733381 * A G 0.213 1.10 5.7E-11 ?
16 51,481,596 rs66998222 G A 0.201 0.91 8.9E-11 SALL1
4 70,634,441 rs2202282 C T 0.497 1.07 8.7E-10 ?
2 11,702,661 rs10929757 A C 0.579 1.08 1.2E-09 GREB1
11 35,085,453 rs2553772 T G 0.538 1.07 4.4E-09 CD44
5 176,450,837 rs2456181 C G 0.484 1.07 6.3E-09 ?
10 105,674,854 rs1265164 A G 0.869 0.91 1.0E-08 OBFC1
The numbers for B allele frequency (B Freq), odds-ratio (OR, where B is the effect allele) and association (P) are based on the UKBB cohort (15,453 UL
cases). Gene symbols are shown for reference. The genomic coordinates follow hg19 and dbSNP build 147. All genome-wide significant (p<5  10 8) loci
and their highest-association SNP are shown.
* Previously implicated predisposition to ULs.
# Previous associations to endometriosis, lung adenocarcinoma, glioma or telomere length; see literature in Appendix 1—table 11
DOI: https://doi.org/10.7554/eLife.37110.005
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(p<10 5) association in both the UKBB (OR = 1.26; p=4.2  10 9) and Helsinki (OR = 1.82;
p=8.1  10 6) cohorts. Figure 3 shows the regional structure and combined association (fixed effect
model p=3.1  10 12) at the locus: the SNP resides on a gene poor region, at a conserved element
that displays activity in uterus-specific H3K27ac and DNaseI data (see ENCODE track details in Sup-
plementary Methods). The SNP is independent of the group of associations at FOXO1 (r2 = 0.0;
Figure 3).
The meta-analysis identified altogether 112 genome-wide significant SNPs not seen in the discov-
ery stage: seven of those were LD-independent (r2 0.3; Appendix 1-table 3) and their UKBB log-
Figure 3. Meta-analysis of UL risk revealed rs117245733 at a gene poor region of 13q14.11. (A) meta-analysis P-values and the genomic context at the
locus. Gene symbols and ENCODE tracks (details in Supplementary Methods) are shown for reference; coordinates follow hg19. (B) Hi-C, TADs and
CpG methylation around the locus with a 1 Mb flank. The needle plot shows the meQTL associations (dashed lines at 10% FDR; green line denotes the
SNP; gray ticks denote all CpGs tested; blue needle for positive coefficient, red for negative coefficient) for tumors (above x-axis; nAA = 53, nAB = 3) and
normals (below x-axis; nAA = 33, nAB = 2). (C) UCSC genome browser tracks related to conservation and regulation at the locus.
DOI: https://doi.org/10.7554/eLife.37110.006
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Figure 4. The genomic risk score is elevated in patients with MED12-mutated lesions and in respect to the UL phenotype in the six follow-up cohorts.
On top, GRS association to MED12 mutation status. The rest show GRS association to the UL phenotype in six independent replication cohorts.
Associations (P) and test statistics (W) are from Wilcoxon rank-sum tests. Only females were included as the control samples. The X-axes show the GRS
distributions for each phenotype.
Figure 4 continued on next page
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Figure 4 continued
DOI: https://doi.org/10.7554/eLife.37110.007
Figure 5. Methylation and expression differences in WNT4. (A), Hi-C, TADs and CpG methylation around the locus with an 1 Mb flank. The needle plot
shows the meQTL associations (dashed lines at 10% FDR; green lines denote the two SNPs, rs2235529 and rs2092315; gray ticks denote all CpGs
tested; blue needle for positive coefficient, red for negative coefficient) for tumors (above x-axis; nAA = 40, nAB = 15, nBB = 1 for rs2235529 and
nAA = 32, nAB = 23 for rs2092315) and normals (below x-axis; nAA = 23, nAB = 12 and nAA = 17, nAB = 17, nBB = 1). (B), Methylation differences in tumors
(n = 56) at CpG chr1:22456326 by SNP rs2235529. (C), WNT4 expression differences in tumors (n = 41) stratified by the rs12042083 genotype. B is the
risk allele, and the P-value is corrected for local multiple testing (permutation based test).
DOI: https://doi.org/10.7554/eLife.37110.008
Välimäki et al. eLife 2018;7:e37110. DOI: https://doi.org/10.7554/eLife.37110 8 of 50
Research article Genetics and Genomics
odds weights were appended to the initial GRS model. The final GRS model of 57 SNPs and their
UKBB-based weights is given in Appendix 1—table 4. Supplementary file 1 gives further details on
the meta-analysis results and heterogeneity statistics.
Replication of the GWAS and GRS
The third stage replicated the observations in NFBC and in five different ethnic groups. In NFBC, the
SNP identified in the stage two meta-analysis, rs117245733 at 13q14.11, was replicated (p=0.034;
linear mixed model; OR = 1.50; 95% CI 1.03 – 2.19). Additional analysis of all 57 SNPs did not reveal
other associations: Supplementary file 2 gives further details on the meta-analysis results and het-
erogeneity statistics. The association between the GRS and UL phenotype was significant
(p=1.1 10 5; Wilcoxon rank-sum; adjusted p=1.1  10 4; one-tailed; W = 4.7  105) in NFBC.
These case-control distributions of GRS are displayed in Figure 4.
UL susceptibility is known to vary by ancestry (Wise et al., 2012). Five different ethnic groups -
African, Caribbean, Irish, Indian and ‘other white’ background - were available from the UKBB
cohort. A total of 2,212 UL cases and 21,054 female controls could be utilized for replication
(Appendix 1—table 1). Supplementary file 3 includes all the 57 SNPs and their summary statistics
in these five cohorts, together with heterogeneity estimates. Due to the small cohort sizes, none of
the single-SNP associations passed genome-wide significance. The GRS model replicated with a sig-
nificant phenotype association in all five ethnicities (Appendix 1-Table 6). A summary of test statis-
tics, GRS distributions and the numbers of cases and controls for each population is given in
Figure 4. A more detailed summary of the GRS model and receiver operating characteristic (ROC)
curve of each cohort are given in Appendix 1—figure 5.
The self-reported ‘Black African’ (mean GRS 4.83) had an outstanding risk-load compared to Cau-
casian (self-reported ‘White Irish’; mean GRS 4.04) background (Figure 4; Wilcoxon rank-sum
p<10 15). As expected (Wise et al., 2012), the African ethnicity displayed an increased prevalence
(19%) compared to the Irish (6%). Assuming that the observed GRS weights have a linear relationship
to the true risk, the GRS difference between African and Irish ancestries explains 9.0% of the
increased prevalence in the African population.
Similar population-specific GRSs could be estimated for the seven populations in the gnomAD
database (Appendix 1—table 7). Appendix 1—figure 6 shows an overview of the GRS for each of
the populations. African ancestry has been shown to carry a two-to-three times higher prevalence
when compared to Caucasian ancestry (Wise et al., 2012). Based on the gnomAD frequencies, the
increased GRS of African ancestry explains between 8 – 16% of this population difference.
Association to clinical variables
The number of ULs per patient had a significant positive association to GRS (negative binomial
regression p=0.001; adjusted p=0.0032; rate ratio 1.25; 95% CI 1.09 – 1.43 for one-unit increase in
GRS; Appendix 1—figure 7). No association was found between GRS and age at hysterectomy
(Appendix 1—table 6). Testing the 57 GRS SNPs separately did not reveal any associations that
pass FDR (Appendix 1—table 5).
Association to MED12 mutated tumors
Our UL set of 1481 lesions included 1159 (78%) mutation-positive and 322 mutation-negative
tumors. The occurrence of mutant tumors did not distribute evenly among the 457 patients. In total
221 (48%) and 123 (27%) patients had all their tumors identified as either MED12-mutation-positive
or -negative, respectively, suggesting that genetic or environmental factors contribute to the pre-
ferred UL type in affected individuals, as previously observed (Mäkinen et al., 2011). Indeed, the
221 mutation positive patients were found to have a significantly higher GRS (Wilcoxon rank-sum
p=7.9  10 4; adjusted p=0.0032; two-sided; W = 1.6  104). This difference in GRS distributions is
visualized in Figure 4.
Comparison against the population controls (n = 8899 females) revealed that the above-men-
tioned patient groups differ by their effect size: the MED12-mutation-positive (221) subset of
patients had an odds ratio of 2.28 for one-unit increase in GRS (95% CI 1.80 – 2.88) compared to the
controls, while the mutation-negative (123) subset had an odds ratio of 1.20 (95% CI 0.88 – 1.66).
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Thus, the majority of the compiled case-control association signal had arisen from the MED12-muta-
tion-positive subset of the patients.
The number of MED12-mutation-positive tumors per patient had a significant positive association
to GRS (p=3.2  10 4; adjusted p=0.002; negative binomial model rate ratio 1.43; 95% CI 1.13 –
3.83 for one-unit increase in GRS; Appendix 1—figure 8). No association between the number of
MED12-mutation-negative tumors and GRS was found (adjusted p=0.053; Appendix 1—figure 8).
The GWAS signal near MED12 was inspected for any associations to somatic MED12 mutations.
Strikingly, the risk allele (rs5937008) did significantly increase the number of MED12-mutation-posi-
tive tumors (p=0.0087; negative binomial model rate ratio 1.23; 95% CI 1.05 – 1.44). Among our 457
patients, the median number of MED12-mutation-positive tumors increased from one to two for the
risk allele carriers. The risk locus and its effect on the number of MED12-mutation-positive tumors is
visualized in Figure 2. An additional analysis of each of the 57 GRS SNPs did not reveal any further
associations (Appendix 1—table 5).
Association to gene expression
All the genome-wide significant SNPs from UKBB and the meta-analysis stage (altogether 1,540
SNPs) were tested with a permutation based approach. In total 34 and 24 genes passed the local
permutation significance threshold (p<0.05) for tumor and matched myometrium data, respectively
(Appendix 1—table 8). Among the hits in tumors were WNT4 (p=0.01; permutation test) and
CDC42 (p=0.03) at 1 p, TNRC6B (p=0.02) at 22q, FOXO1 (p=0.03) at 13q, and DMRT1 (p=0.04) at 9
p. None of the local associations passed a genome-wide FDR of 10%. No significant association was
observed between the risk allele and MED12 expression (rs5936989; Appendix 1—figure 11). The
full list of eQTL statistics can be found from Supplementary file 4.
Association to DNA methylation
Our analysis of the 57 GRS SNPs revealed altogether 17,030 (9,466 in tumors and 7564 in matched
myometrium) cis methylation quantitative trait loci (cis-meQTL) with nominal p<0.05. Of these, 145
passed a 10% FDR. Of the plausible predisposition genes, FOXO1, TERT and WNT4 showed signifi-
cant meQTL associations (Appendix 1—table 9). All the cis-meQTLs and annotation for their geno-
mic context are in Supplementary file 5.
Association to telomere length and structural variants
The UL predisposition loci at TERT, TERC and OBFC1 were examined for an effect on telomere
length. Overall the telomere length was significantly shorter in tumors than in adjacent matched
myometrium (p=0.01; Kruskal-Wallis), as previously reported (Rogalla et al., 1995; Bonatz et al.,
1998). One of the risk alleles at TERT (rs2736100) was significantly associated with shorter telomere
length (p=0.01; Kruskal-Wallis) (Appendix 1—figure 12). Adjusting for the patient age did not
explain away the association. The association was not seen in myometrium. The other two LD-inde-
pendent SNPs at TERT, rs72709458 and rs2853676, or the SNPs at TERC (rs10936600) and OBFC1
(rs1265164) did not show association to telomere length (p=0.24, p=0.57, p=0.07 and p=0.48,
respectively; Kruskal-Wallis). The combined effect of TERT (rs72709458, rs2736100, rs2853676),
TERC (rs10936600) and OBFC1 (rs1265164) had a negative trend with telomere length (p=0.055; lin-
ear model 95% CI  408.5 – 4.7 per one risk allele; see Appendix 1—figure 13). In whole genome
sequencing data, no association was detected between genotype and the number of somatic struc-
tural variants.
Pathway enrichment
The DEPICT framework (Pers et al., 2015) was ran using the genome-wide significant SNPs from the
UKBB cohort, in total 1,069/1,428 autosomal SNPs. The resulting target gene prioritization, pathway
enrichment and tissue enrichment results are given in Supplementary file 6. The analysis did not
reveal any significant enrichments with the exception of one pathway related to induced stress. ATM
was the highest ranking target gene, and uterus/myometrium were among the highest ranking tissue
types.
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Previously proposed UL predisposition loci
Previous UL association studies (Cha et al., 2011; Zhang et al., 2015; Eggert et al., 2012;
Hellwege et al., 2017) have reported altogether seven genome-wide significant UL susceptibility
loci. Two out of the seven loci - that is, 22q13.1 (at TNRC6B) and 11p15.5 (at BET1L) - replicated in
UKBB using 15,453 cases and 392,628 controls. Cha et al (Cha et al., 2011). highlight OBFC1 (at
10q24.33) as a candidate gene and, while the SNP that they reported does not replicate in UKBB,
the OBFC1 region is identified in our discovery stage (rs1265164; Table 1). See Appendix 1—table
10 for a summary of these results.
Discussion
The UK Biobank genotype-phenotype data revealed 22 novel predisposition loci for UL, most of
them in close proximity to highly plausible predisposition genes. The combined UL risk of these loci
was replicated in a subsequent analysis of the polygenic risk score (GRS) in six independent cohorts
from different ethnic backgrounds. Our multi-ethnic replication implies that the discovered loci are
indeed involved in UL development, and the early UL association studies have likely been underpow-
ered to detect them. Three previously reported loci, at OBFC1 (Cha et al., 2011), TNRC6B
(Cha et al., 2011; Edwards et al., 2013a; Aissani et al., 2015; Bondagji et al., 2017) and BET1L
(Cha et al., 2011; Edwards et al., 2013b), were also validated, however, the mechanistic connection
to UL development remains obscure for the latter two.
Though simple association is not sufficient to formally prove causality, 14 out of the 22 risk loci
harbor plausible predisposition genes. These genes can be divided into two groups: TERT, TERC,
OBFC1 (all involved in telomere length), ATM and TP53 guard stability of the genome. ESR1,
GREB1, WT1, MED12, WNT4, FOXO1, DMRT1, SALL1, and CD44 play a role in genitourinary
development.
Estrogen is a well-known inducer of UL growth (Borahay et al., 2015). The top association at
6q25.2 (rs58415480) resides within intron 107 of Spectrin Repeat Containing Nuclear Envelope Pro-
tein 1 (SYNE1), 130 kb downstream of ESR1, the latter being the only gene that resides completely
within the topologically associating domain (TAD; Appendix 1—figure 1). While the role of estrogen
in leiomyomagenesis has been firmly established, this is the first genetic evidence to this end. The
lead SNP at 2 p resides in the third exon of the gene GREB1. GREB1 is an essential regulatory factor
of ESR1 (Mohammed et al., 2013).
WT1, WNT4 and FOXO1 are central factors in uterine development and in the preparation for
pregnancy (decidualization) in endometrium (Biason-Lauber and Konrad, 2008; Hill, 2018;
Kaya Okur et al., 2016; Tamura et al., 2017). Perturbations in their function are known to have neo-
plastic potential. The strongest association at 11p13 (rs10835889) is 40 kb downstream of the closest
gene WT1, at a region with enhancer activity (Appendix 1—figure 1). WT1 is a transcription factor
that acts as both a tumor suppressor and an oncogene (Yang et al., 2007). The lead SNP at 1p36.12
(rs2235529) resides at the second intron of WNT4. The risk allele is associated with suggestive upre-
gulation of WNT4 (Figure 5C). WNT4 is known to be overexpressed in uterine leiomyomas with
MED12 mutations (Markowski et al., 2012), and knock-down of MED12 in UL cells reduces WNT4
expression (Al-Hendy et al., 2017). The risk locus in 1p36.12 was also associated with several
meQTLs suggesting that methylation may have a role in WNT4 regulation (Figure 5). WNT4 encodes
a signaling protein that has a crucial role in sex-determination (Vainio et al., 1999), and the WNT
signaling pathway has a well-established role in various malignancies such as breast and ovarian can-
cer (Peltoketo et al., 2004). Of note, recent GWAS on gestational duration suggested that binding
of the estrogen receptor at WNT4 is altered by rs3820282 (r2 = 0.92 with our lead SNP)
(Zhang et al., 2017). Both WNT4 and FOXO1 are decidualization markers regulated by ESR1
(Kaya Okur et al., 2016). Though these considerations support WNT4 as a candidate predisposition
gene at this locus, the near-by CDC42 has been shown to play a role in uterine pathology, in particu-
lar endometriosis (Powell et al., 2016), and should not be overlooked in further work.
Also MED12 has been implicated in uterine development in a mouse model (Wang et al.,
2017a). DMRT1 is a transcription factor associated with male sex-development (Lindeman et al.,
2015). CD44 is a plausible fibroid stem cell marker (Mas et al., 2015). Mutations in SALL1 and a
deletion at the GWAS signal have been associated with Townes-Brocks syndrome, a condition
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associated with kidney malformations (Stevens and May, 2016). Thus genes involved in genitouri-
nary development are strikingly associated with UL predisposition.
ATM, TP53, TERT, TERC and OBFC1 could be involved in uterine neoplasia predisposition
through genetic instability and telomere maintenance. The lead SNP at 11q (rs141379009) resides in
the 22nd intron of ATM, and the SNP at 17 p in the 30-untranslated region of TP53. ATM and TP53
are involved in DNA damage response (Guleria and Chandna, 2016), and they are among the rela-
tively few genes that have been found to be recurrently mutated in leiomyosarcoma (Lee et al.,
2017). TERT and TERC encode subunits of the telomerase enzyme, which guards chromosomal sta-
bility by elongating telomeres (Blasco, 2005). In addition OBFC1 has been associated with telomere
maintenance (Lee et al., 2013). TERT is expressed in germ cells as well as in many types of cancers
(Blasco, 2005). The neoplasia predisposing effect of the risk alleles at the TERT locus (rs72709458;
rs2736100; rs2853676) has been overwhelmingly documented (Appendix 1—table 11). Previous
studies have reported contradicting observations on the effect of rs2736100 on telomere length
(Liu et al., 2014; ENGAGE Consortium Telomere Group et al., 2014; Lan et al., 2013;
Melin et al., 2012; Choi et al., 2015). ULs have been shown to display shortened telomeres
(Rogalla et al., 1995; Bonatz et al., 1998), potentially provoking chromosomal instability as the
lengths of chromosome telomeres are diminished. In our patient cohort, the risk allele at TERT
(rs2736100) is significantly associated with shorter telomere length (Appendix 1—figure 12),
whereas the combined effect of SNPs at TERT, TERC and OBFC1 did not reach statistical
significance.
GRS associated merely with a susceptibility to the most common UL subtype, MED12 mutation
positive tumors. Indeed it has been known that MED12-mutation-positive tumors do not distribute
randomly among patients (Mäkinen et al., 2011), and our data provide at least a partial explanation
to this intriguing finding. An outstanding susceptibility locus was identified 250 kb upstream of
MED12: our in-house patient cohort - together with a mutation-screening of their 1481 tumors -
revealed that the risk allele could facilitate selection of somatic MED12 mutations. It may be that
environmental factors contribute more significantly to genesis of MED12 wild-type lesions. In our
recent study this tumor type was associated with a history of pelvic inflammatory disease, and thus
infectious agents could be one underlying factor (Heinonen et al., 2017). Obviously, also the power
of GWAS to detect genetic associations to rare UL subtypes – such as the HMGA2 overexpressing
or FH deficient subtypes – is reduced.
This work highlights several new genetic cornerstones of UL formation, highlights genitourinary
development and maintenance of genomic stability as key processes associated with it, and repre-
sents another step towards a much-improved understanding of its molecular basis. The proposed
risk score can stratify the female population to low and high-risk quartiles that differ by two-fold in
their UL risk. The population-specific risk score was inflated towards the African and Caribbean
cohorts, which connects the predisposition loci to the excess UL prevalence in these ethnicities.
While the increased risk appears minor on an individual level, the population-level burden to wom-
en’s health arising from these risk loci is highly significant considering the incidence of the condition.
Together with the recent progress in molecular tumor characterization and subclassification, the
identification of the genetic components of UL predisposition should pave the way towards more
sophisticated prevention and management strategies for these extremely common tumors. The risk
SNP with the most immediate potential value is that at estrogen receptor alpha, and our findings
should fuel much further work on the interplay between individual germline genetics, endogenous
and exogenous hormonal exposure, and occurrence and growth rate of UL.
Materials and methods
Genome-wide association study
Figure 1 provides an outline of the four stages that were implemented. The discovery stage was
conducted with UK Biobank resources (UKBB; project #32506; accessed on April 10, 2018). The
resource included pre-imputed genotypes (version 3; March 2018) for a total of 487,409 samples
(486,757 samples for the X chromosome) and 96 million SNPs. The background information on the
imputation and data quality control (QC) can be found through the UKBB documentation (www.
ukbiobank.ac.uk).
Välimäki et al. eLife 2018;7:e37110. DOI: https://doi.org/10.7554/eLife.37110 12 of 50
Research article Genetics and Genomics
The UL cases were identified on the basis of both the self-reported uterine leiomyoma (UL) phe-
notype (UKBB data-field 20002: Non-cancer illness code 1351) and International Classification of Dis-
eases (ICD) codes (data-fields 41202 – 41205: Main and secondary diagnosis for ICD10 code D25
and ICD9 code 218). These phenotype data resulted in a total of 20,106 UL cases prior to any sam-
ple/genotype QC.
Sample QC was based on the UKBB annotation as follows. In total 409,692 samples passed the
initial QC on ethnic grouping (UKBB data-field 22006): self-identified as ‘White British’, and similar
genetic ancestry based on a principal component analysis (PCA) of the genotypes. Further sample
QC excluded excess kinship (field 22021; 408,797 samples passed), sex-chromosome aneuploidy
(field 22019; 408,241) and inconsistent gender (fields 31 and 22001, and one male with self-reported
ULs; 408,081). In total 15,453 UL cases and 392,628 population-matched controls (205,157 females
and 187,471 males) passed all these criteria.
Raw genotype calls (UKBB version 2; Affymetrix UK BiLEVE Axiom, or Affymetrix UKBB Axiom
array) were available for 805,426 SNPs: after filtering out low genotyping rate (<95%), Hardy-Wein-
berg equilibrium (p<10 10) and minor allele frequency (MAF) <0.001, the remaining 611,887 autoso-
mal genotypes were used to train the mixed model for association testing. Imputed SNPs with
MAF <0.001 and imputation score (INFO) <0.3 were excluded. Further SNPs were excluded due to
imputation panel differences between cohorts, and the remaining 8.3 million SNPs (Haplotype Refer-
ence Consortium, HRC1.1 panel) were tested for case-control association with BoltLMM (version
2.3.2) (Loh et al., 2015). The default linear, infinitesimal mixed model was used to adjust for any
underlying population structure. The model included categorical covariates for the 22 UK Biobank
assessment centres and two genotyping arrays.
Meta-analysis
The second stage meta-analysis utilized the genome-wide summary statistics from UKBB and the
Helsinki cohort of 457 UL cases and 15,943 controls. Details on the Helsinki cohort’s imputation,
sample and genotype QC are given in the Supplementary Methods. A total of 8.3 million SNPs
passed imputation QC and were utilized in the meta-analysis with PLINK (version 1.90b3i)
(Chang et al., 2015).
Replication
The SNPs were tested for association in six independent cohorts: Northern Finland Birth Cohort
(NFBC) and five non-overlapping subsets of UKBB. In addition to the single-SNP association tests, a
polygenic risk score (Abraham and Inouye, 2015Abraham and Inouye, 2015) was compiled as fol-
lows. The genomic risk score (GRS) was computed as a sum over SNP dosages weighted by their
observed log-odds: LD pruning (r2 0.3) was applied in the order of UKBB association, and the
remaining, genome-wide significant SNPs were chosen for the GRS. The log-odds weights were
taken from the UKBB statistics (i.e. logarithm of the dosage-based ORs). The resulting GRS model
was evaluated using R (3.3.1) and the packages PredictABEL (1.2 – 2) and MASS (7.3 – 45).
The Northern Finland Birth Cohort (NFBC) had in total 459 UL cases and 4943 controls; details of
the imputation, sample and genotype QC are given in the Supplementary Methods.
Five non-overlapping, self-reported population-strata were available from UKBB (data-field
21000) and could be utilized as an independent replication: the five self-reported ancestries were
‘Black African’, ‘Black Caribbean’, ‘Indian’, ‘White Irish’ and ‘Other white background’. Sample QC
excluded excess kinship (field 22021), sex-chromosome aneuploidy (field 22019) and inconsistent
gender (fields 31 and 22001). The numbers of cases and controls that passed the sample QC can be
found in Figure 1. A summary of background variables is given in Appendix 1—table 1. These five
sample subsets did not overlap with the discovery GWAS individuals. A collection of ancestry-infor-
mative genotypes was utilized to assess the genetic homogeneity of each of the self-reported ances-
try (details in Supplementary Methods).
Patient and tumor material
Our in-house patient and tumor data were investigated regarding the identified risk loci. All tumors
of 1 cm diameter had been harvested and stored fresh-frozen (details in Supplementary Methods).
MED12 mutations were screened by Sanger sequencing the MED12 exons 1 and 2 and their flanking
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sequences (60 bp) from all uterine leiomyoma and matching normal myometrium samples
(Mäkinen et al., 2011; Heinonen et al., 2014). The resulting sequence graphs were inspected man-
ually and with Mutation Surveyor software (Softgenetics, State College, PA). Clinical patient data
was available for the number of ULs, menopause status, parity, body mass index (BMI) and age at
hysterectomy (Appendix 1—figure 2). This study was conducted in accordance with the Declaration
of Helsinki and approved by the Finnish National Supervisory Authority for Welfare and Health,
National Institute for Health and Welfare (THL/151/5.05.00/2017), and the Ethics Committee of the
Hospital District of Helsinki and Uusimaa (HUS/177/13/03/03/2016).
Expression quantitative trait loci analysis
For the cis expression quantitative trait loci (cis-eQTL) analysis, genes with less than six reads in over
80% of the samples were filtered out. The between sample normalization was done with Relative
Log Expression (RLE) normalization and each gene was inverse normal transformed. The eQTL analy-
sis was run with FastQTL (version 2.184) (Ongen et al., 2016) separately for 60 tumors and 56
patient-matched unaffected, adjacent myometrium samples using permutation approach. The per-
mutation parameter was set to ‘1000 10000’. Sequencing batch was used as a covariate. The cis-
region was set to be 2 Mb. FDR correction was applied for tumors and matched myometrium
separately.
Methylation quantitative trait loci analysis
DNA methylation was studied in 56 tumors and 36 matched myometrium samples. The methylation
calls were analyzed with bsseq (version 1.12.2) (Hansen et al., 2012). Only the methylation in CpG
context was considered. Every locus was required to have the coverage of 2 in at least 90% of sam-
ples. The association between methylation and genotype was studied with MatrixEQTL (version
2.1.1) using a linear regression model (Shabalin, 2012). The LD-independent (r2 0.3) SNPs from
the discovery stage (Appendix 1—table 2) and meta-analysis (Appendix 1—table 3) were consid-
ered (altogether 57 SNPs). The SNPs with MAF <0.05 in the methylation samples were filtered out.
This resulted in 44 SNPs in tumors and 45 SNPs in matched myometrium. Cis methylation quantita-
tive trait loci (cis-meQTL) was determined to be within 1 Mb flank from the SNP of interest. To anno-
tate the CpGs with genomic context, the overlap between UCSC’s gene track (hg19) and known
CpG islands was studied. As the role of promoter methylation is well known, promoter methylation
was studied in addition to gene body methylation. Core promoter was defined as a region  2 kb
and +1 kb from the transcription start site. The methylation analysis was performed separately for
tumors and matched normal myometrium to study whether the changes in methylation could be
observed in both tissues.
Whole genome analysis
The whole genome sequenced (WGS) samples, in total 71 tumors (48 Illumina, 23 Complete Geno-
mics) and 51 matched myometrium samples (28 Illumina and 23 Complete Genomics), were pre-
pared following Illumina and Complete Genomics protocols and processed as described previously
(Mehine et al., 2013). Structural variation was defined as a structural rearrangement (e.g deletion,
inversion or translocation) not detectable in matched normal myometrium. Structural variation was
detected as described in Mehine et al. (Mehine et al., 2013) The mean telomere length was esti-
mated for Illumina samples using Computel (version 0.3) (Nersisyan and Arakelyan, 2015) with the
default settings. Clonally related tumors were excluded from the analysis by randomly sampling one
tumor to represent each clonally related tumor group. Clonally related tumors had identical changes
in driver genes and shared at least a subset of somatic copy-number changes and/or copy neutral
loss of heterozygosity (see Mehine et al. (Mehine et al., 2015) for further details in identification of
the clonally related tumors). Kruskal-Wallis test was used to assess the telomere length differences
between tumors and matched myometrium as well as between genotypes. Linear model was used
to calculate the association between number of risk alleles and telomere length.
Pathway enrichment
Pathway enrichment of all genome-wide significant SNPs was tested with DEPICT (version 1 release
194) following the default settings (Pers et al., 2015). The tool is designed to integrate multiple
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GWAS loci for in silico target gene prioritization, pathway enrichment and tissue-specific expression
profiling. In short, the DEPICT framework combines phenotype-free co-expression networks, prede-
fined pathways and protein-protein interaction networks in order to reveal functionally connected
genes among the multiple risk loci. The tool is restricted to autosomal SNPs.
Statistical analysis
Meta-analysis was implemented with an inverse-variance weighted, fixed effect model. Associations
between the risk alleles and other variables were tested assuming an additive genotype model
unless otherwise noted. The DHARMa (0.1.5) package was applied to evaluate the goodness-of-fit of
the binomial and negative binomial models. The contribution of GRS to prevalence was estimated
by [(Ea/Pi-1)/(Pa/Pi-1)], where Ea = Pi*GRSa/GRSi assumes a linear relationship between GRS and the
true risk, and Px and GRSx are the population-specific prevalence and mean GRS, respectively. All
statistical tests were two-tailed unless otherwise noted.
Summary statistics were collected from each of the study stages and are available as Appen-
dix 1—table 2 and Supplementary file 1–3. For each SNP, we report its allele frequency, effect size
estimates and association based on the default linear, infinitesimal mixed model. For the meta-analy-
sis stages, we also report the Cochrane’s Q statistic and I2 heterogeneity index in addition to the
fixed-effects meta-analysis association and effect size (random-effects meta-analysis is included for
reference). BoltLMM reported lambda (lGC) 1.055, 1.045 and 1.016 for UKBB, Helsinki and NFBC,
respectively. The X chromosome associations were processed separately and included only the
female controls (lGC 1.052, 1.049 and 1.005 for UKBB, Helsinki and NFBC, respectively).
For GWAS, p<5  10 8 was reported as significant. The GRS association tests (Appendix 1—
table 6) were controlled for family-wise error rate (FWER) and reported significant for Holm-Bonfer-
roni adjusted p<0.05. Large families of association tests were controlled for false discovery rate
(FDR; Benjamini-Hochberg method) and noted significant at FDR < 10%. In the six telomere length
association tests and the two structural variation association tests, p<0.05 was considered statisti-
cally significant.
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The UK Biobank (UKBB) individuals were divided into six distinct subsets based on their self-
reported ancestry. A summary of the background variables for each of the six ancestries is
given in Appendix 1—table 1.
Sample QC for the discovery subset was readily available from the UKBB annotation (data-
field 22006): self-identified as ‘White British’, and similar genetic ancestry based on a principal
components analysis (PCA) of the genotypes.
The small replication cohorts were assessed for genetic homogeneity based on PCA of
ancestry informative markers as follows. We pooled together 21 panels of ancestry informative
markers - in total 1396 unique, autosomal SNPs, see Soundararajan et al
(Soundararajan et al., 2016). for references - and compared the resulting PCs against the self-
reported ancestry information. As expected, the genetic differences at these informative
markers separated each self-reported ancestry into a distinct, homogeneous cluster. See
Appendix 1—figure 4 for the resulting clustering of the follow-up cohorts.
Helsinki cohort
Our patient cohort (Helsinki cohort) was collected in accordance with the Declaration of
Helsinki and approved by the Finnish National Supervisory Authority for Welfare and Health,
National Institute for Health and Welfare (THL/151/5.05.00/2017), and the Ethics Committee
of the Hospital District of Helsinki and Uusimaa (HUS/177/13/03/03/2016). In total 1577
uterine leiomyoma and corresponding normal myometrial samples were collected as fresh-
frozen from 480 patients undergoing hysterectomy as previously described (Mäkinen et al.,
2011; Heinonen et al., 2014; Heinonen et al., 2017). See below details on numbers of
samples that passed imputation QC.
The number of ULs per patient was determined by the number of ULs harvested from the
hysterectomy specimens. The study materials were derived from six different tissue
collections, one consisting of anonymous patients and the other five collections consisting of
patients who signed an informed consent before entering the study. Pathologists dissected
the hysterectomy specimens and collected all visible tumours from each patient, with the
exception of one tissue collection in which all feasible distinct tumours  1 cm in diameter
were harvested. The smallest lesion used in this study had a diameter of 4 mm. All the
specimens underwent routine diagnostic pathological scrutiny, and the histopathological
diagnosis for the study samples was retrieved from the pathology reports.
Population-matched control data were obtained from the National FINRISK Study
containing 16,048 genotyped individuals (https://www.thl.fi/fi/web/thlfi-en/research-and-
expertwork/population studies/the-national-finrisk-study).
Northern Finland cohort
The Northern Finland Birth Cohort (NFBC) is a prospective collection of Oulu and Lapland
region individuals born in 1966. For further validation of our results, the NFBC Project Center
(University of Oulu) provided phenotype information on both clinical ICD disease records and
46 year follow-up questionnaires. The genotyped individuals (dbGaP Study Accession:
phs000276.v2.p1) had in total 459 UL cases and 4943 population-matched controls.
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Genotyping arrays
The Helsinki cohort was genotyped with Illumina Infinium HumanCore-24 BeadChip. The
control samples in the Helsinki cohort were genotyped with the Illumina HumanCoreExome
SNP array. The NFBC individuals were genotyped with the Illumina Infinium SNP array. All
genomic coordinates follow GRCh37 and dbSNP build 147.
SNP array data processing and imputation
The Helsinki cohort B-allele frequencies and log-R ratios were extracted with Illumina
GenomeStudio software, and somatic allelic imbalance (AI) regions were calculated for all
tumors using BAFsegmentation (Kim et al., 2015) with default parameters.
Quality control (QC) was implemented using PLINK (v1.90b3i; http://www.cog-genomics.
org/plink/1.9/). The Helsinki cohort was inspected for outliers, close relatedness and low
genotyping rate: 457 UL cases (representing 1481 tumors collected) and 15,943 controls
passed the initial genotyping control. Further genotype QC was implemented to exclude
SNPs with low genotyping rate (<95%), excess homozygosity (i.e. homozygotes that exceed
respective heterozygotes), rare homozygotes (minor allele frequency, MAF <0.02), Hardy-
Weinberg equilibrium (p<10 3) or incorrect strand assignment based on LD. The remaining
211,967 SNPs were imputed using the Haplotype Reference Consortium panel (HRC; release
1.1) at the Sanger Imputation service (EAGLE2 +PBWT; https://imputation.sanger.ac.uk). All
the reported alleles follow the strand orientation in HRC1.1 and GRCh37 coordinates. The
same quality controls were applied to the NFBC data: all 5402 samples passed QC, and the
GRS SNPs were imputed following the same process as for the Helsinki cohort. Post-
imputation QC of Helsinki and NFBC data excluded SNPs with MAF <0.005 and imputation
score (INFO) <0.4. A total of 8.3 million SNPs passed imputation quality.
Clinical background information
Clinical data were collected based on a retrospective review of medical records of the Helsinki
study subjects. Details are provided in Heinonen et al (Heinonen et al., 2017). Information on
parity, BMI, number of leiomyomas and age at hysterectomy were quantified for a total of
n = 367, 366, 457 and 392 patients, respectively. Menopausal status was recorded for 367
patients as either pre, post or current HRT (hormone replacement therapy). Appendix 1—
figure 2 shows the summary statistics of each background variable.
RNA sequencing
RNA-seq libraries were prepared according to the standard quality requirements for Illumina
TruSeq Stranded total-RNA (RiboZero) kit. Paired-end Illumina (HiSeq2500) sequencing
produced around 60 to 70 million 2  125 bp reads per sample. Data were aligned to human
reference transcript (GRCh37) with HISAT2 (2.1.0) using parameter -dta and setting rna-
strandness to RF (Kim et al., 2015). The alignments were assembled with StringTie (1.3.3b)
using parameters -e and -rf (Pertea et al., 2015). Data quality was controlled by checking
HISAT2 mapping statistics, ribosomal RNA contamination (based on Ensembl annotation
release 75) and batch effects (principal components analysis).
DNA methylation
The SureSelect target enrichment system (Agilent Technologies, Inc., CA, USA) covering 84.5
Mb of the genome was used to prepare bisulfite-sequencing samples. Sample preparations
were done according to the manufacturer’s instructions. Illumina paired-end sequencing of 56
tumor and 36 normal samples was done in Karolinska Institutet (Sweden) using 100 bp read
length and the HiSeq2000 platform.
Raw sequencing reads were quality and adapter trimmed with cutadapt version 1.3 in Trim
Galore. Low-quality ends trimming was done using Phred score cutoff 30. Adapter trimming
Välimäki et al. eLife 2018;7:e37110. DOI: https://doi.org/10.7554/eLife.37110 22 of 50
Research article Genetics and Genomics
was performed using the first 13 bp of the standard Illumina paired-end adapters with
stringency overlap two and error rate 0.1. Read alignment was done against hg19/GRCh37
reference genome downloaded from UCSC Genome Browser with Bismark (version v0.10.0)
(Krueger and Andrews, 2011) and Bowtie 2 (version 2.0.0-beta6) (Langmead and Salzberg,
2012). Duplicates were removed using the Bismark deduplicate function. Extraction of
methylation calls was done with Bismark methylation extractor discarding the first 10 bp of
both reads and reading methylation calls of overlapping parts of the paired reads from the
first read (–no_overlap parameter).
LocusZoom visualization and ENCODE tracks
LocusZoom (http://locuszoom.org/) plots include the ENCODE tracks for DNase I
hypersensitive sites for hTERT-HM (ENCFF001SPI, ENCFF001UXF) and uterus (ENCFF689EGI).
RAMPAGE tracks were included for uterus (ENCFF979EGO), myometrium (ENCFF605TKQ)
and endometrial microvascular endothelial cells (ENCFF440YZN) experiments. Topologically
associating domains from endometrial microvascular endothelial cells (HiC; ENCFF633ORE)
and H3K27ac ChIP-seq from uterus (stable peaks; ENCFF045LNJ) were included. Additional
uterus-specific ChIP-seq data for CTCF (ENCFF282BOE, ENCFF634DDY) and POLR2A
(ENCFF822OTY, ENCFF164YIY) were also included. Hi-C figures were produced with the ‘3D
genome browser’ (http://promoter.bx.psu.edu/hi-c/; GM12878) (Wang et al., 2017b).
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Appendix 1—table 2. Discovery stage GWAS for the UKBB cohort. The information for B allele
frequency (B Freq), odds-ratio (OR) and association (Beta; standard error of Beta; c2 and P) were
collected from the UKBB cohort. All genome-wide significant, LD-independent (r2 0.3 pruned in
order of UKBB association) SNPs that passed imputation QC are shown. SNPs with r2 = NA are
the lead-SNPs of each distinct locus. The A and B alleles are on GRCh37 forward strand. OR was
computed from SNP dosages and B as the effect allele. Rows are sorted by genomic position.




freq OR Beta SE c2 P




rs2092315 1 22507684 C T 0.14
(rs2235529)








rs11674184 2 11721535 T G 0.30
(rs10929757)
























rs2736100 5 1286516 C A 0.23
(rs72709458)




rs2853676 5 1288547 T C 0.23
(rs2736100)








rs4870084 6 152543949 C T 0.29
(rs6904757)




rs6928363 6 152546094 G A 0.17
(rs58415480)








rs75510204 6 152592680 T G 0.07
(rs58415480)




rs6904757 6 152593102 A G 0.08
(rs6928363)




rs144444583 6 152684585 T C 0.30
(rs58415480)




rs138821078 9 674217 C G 0.13
(rs10975820)




rs10975820 9 684160 G A 0.00
(rs7027685)








rs114680331 9 815682 T C 0.12
(rs7027685)




rs4742448 9 826585 C G 0.28
(rs7027685)




Appendix 1—table 2 continued on next page
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Appendix 1—table 2 continued




freq OR Beta SE c2 P
rs2277163 9 827224 A G 0.07
(rs7027685)








rs11246003 11 213723 T G 0.00
(rs507139)








rs2207548 11 32368744 C A 0.24
(rs10835889)








rs7120483 11 32406983 G C 0.30
(rs10835889)




rs11031783 11 32459923 C A 0.28
(rs10835889)








rs59021565 11 107999907 C G 0.27
(rs141379009)








rs4988023 11 108168995 A C 0.00
(rs141379009)




rs12223381 11 108354102 C T 0.12
(rs59021565)




rs9669403 12 46798900 G A 0.28
(rs12832777)








rs117245733 13 40723944 G A 0.00
(rs7986407)




















rs5936989 X 70022420 T A 0.27
(rs5937008)








rs7059898 X 70149078 C A 0.27
(rs5937008)




rs7888560 X 131171122 A G 0.19
(rs5930554)








rs5933158 X 131578034 A G 0.21
(rs5930554)




rs5975338 X 131626317 A G 0.28
(rs5930554)
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Appendix 1—table 4. Genomic risk score. Summary of the GRS and its weights based on the
discovery and meta-analysis stages. Dosage-based odds-ratios (OR) and log-odds were
collected from the UKBB summary statistics. The A and B alleles are on GRCh37 forward strand,
and the B allele is the effect allele. In total 50 SNPs from stage 1 and seven SNPs from stage 2.
rs-code Chr Position A B OR Log-odds Stage *
rs2235529 1 22450487 C T 1.14 0.132 Stage 1
rs2092315 1 22507684 C T 1.07 0.072 Stage 1
rs10929757 2 11702661 A C 1.08 0.073 Stage 1
rs11674184 2 11721535 T G 0.94  0.067 Stage 1
rs10936600 3 169514585 A T 0.91  0.095 Stage 1
rs143835293 3 197623337 A G 1.75 0.558 Stage 1
rs62323680 4 54546192 G A 1.16 0.153 Stage 1
rs2202282 4 70634441 C T 1.07 0.071 Stage 1
rs72709458 5 1283755 C T 1.12 0.111 Stage 1
rs2736100 5 1286516 C A 0.91  0.090 Stage 1
rs2853676 5 1288547 T C 0.91  0.089 Stage 1
rs2456181 5 176450837 C G 1.07 0.066 Stage 1
rs4870084 6 152543949 C T 0.92  0.087 Stage 1
rs6928363 6 152546094 G A 0.92  0.078 Stage 1
rs58415480 6 152562271 C G 1.18 0.167 Stage 1
rs75510204 6 152592680 T G 1.29 0.257 Stage 1
rs6904757 6 152593102 A G 0.93  0.078 Stage 1
rs144444583 6 152684585 T C 1.12 0.111 Stage 1
rs138821078 9 674217 C G 1.23 0.205 Stage 1
rs10975820 9 684160 G A 1.12 0.112 Stage 1
rs7027685 9 802228 A T 1.11 0.103 Stage 1
rs114680331 9 815682 T C 1.11 0.108 Stage 1
rs4742448 9 826585 C G 1.07 0.066 Stage 1
rs2277163 9 827224 A G 0.87  0.140 Stage 1
rs1265164 10 105674854 A G 0.91  0.097 Stage 1
rs11246003 11 213723 T G 0.85  0.167 Stage 1
rs507139 11 225196 G A 0.84  0.171 Stage 1
rs2207548 11 32368744 C A 1.09 0.091 Stage 1
rs10835889 11 32370380 G A 1.14 0.133 Stage 1
rs7120483 11 32406983 G C 1.12 0.112 Stage 1
rs11031783 11 32459923 C A 1.09 0.084 Stage 1
rs2553772 11 35085453 T G 1.07 0.069 Stage 1
rs59021565 11 107999907 C G 1.11 0.109 Stage 1
rs141379009 11 108149207 T G 1.32 0.281 Stage 1
rs4988023 11 108168995 A C 0.89  0.113 Stage 1
rs12223381 11 108354102 C T 1.07 0.064 Stage 1
rs9669403 12 46798900 G A 1.07 0.071 Stage 1
rs12832777 12 46831129 T C 1.09 0.086 Stage 1
rs117245733 13 40723944 G A 1.26 0.231 Stage 1
rs7986407 13 41179798 A G 1.09 0.084 Stage 1
Appendix 1—table 4 continued on next page
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Appendix 1—table 4 continued
rs-code Chr Position A B OR Log-odds Stage *
rs66998222 16 51481596 G A 0.91  0.098 Stage 1
rs78378222 17 7571752 T G 1.53 0.427 Stage 1
rs733381 22 40669648 A G 1.10 0.091 Stage 1
rs5936989 X 70022420 T A 0.92  0.081 Stage 1
rs5937008 X 70093038 C T 0.91  0.094 Stage 1
rs7059898 X 70149078 C A 1.07 0.068 Stage 1
rs7888560 X 131171122 A G 1.08 0.077 Stage 1
rs5930554 X 131312089 T C 1.14 0.129 Stage 1
rs5933158 X 131578034 A G 1.08 0.074 Stage 1
rs5975338 X 131626317 A G 1.10 0.094 Stage 1
rs17631680 2 67090367 T C 0.90  0.102 Stage 2
rs1735537 3 128122820 T C 1.07 0.071 Stage 2
rs67751869 4 54568834 T C 1.13 0.121 Stage 2
rs6901631 6 152567047 T C 0.91  0.097 Stage 2
rs11790408 9 876418 G T 0.94  0.063 Stage 2
rs10415391 19 22652436 C T 1.10 0.098 Stage 2
rs62132801 19 49267882 A T 0.90  0.105 Stage 2
* Discovered in stage 1 (UKBB GWAS) or in stage 2 (meta-analysis of UKBB and Helsinki)
DOI: https://doi.org/10.7554/eLife.37110.020
Appendix 1—table 5. Summary of association tests for SNPs. Each of the 57 GRS SNPs was
tested for an additive effect to age at hysterectomy, degree of somatic allelic imbalance (AI)
and tumor counts. Somatic allele imbalance was defined as the mean of the length of somatic
allelic imbalance over all tumors of a patient. Tests of MED12 mutation positive and negative
tumors are denoted by MED12mut + and MED12mut-, respectively. The numbers for
regression coefficient (Beta), standard error of beta (SE), test statistic (z) and association (P)
were taken by fitting either a linear regression or negative binomial (NB) regression model
(response ~predictor). The nominal P-values were adjusted for FDR (Q). The risk allele was used
as the effect allele for Beta. In total 228 tests, all p<0.05 are shown.
Predictor Response Model Beta SE Statistic P Q
12:46798900:G:A MED12mut + count NB  0.22 0.08  2.88 0.004 0.51
9:674217:C:G MED12mut + count NB  0.69 0.26  2.63 0.008 0.51
X:70093038:C:T MED12mut + count NB 0.21 0.08 2.62 0.009 0.51
X:70022420:T:A MED12mut + count NB 0.20 0.08 2.56 0.011 0.51
11:32459923:C:A MED12mut + count NB 0.23 0.09 2.54 0.011 0.51
4:54568834:T:C log(somatic AI basepairs) Linear  0.25 0.10  2.48 0.013 0.51
17:7571752:T:G MED12mut- count NB  0.92 0.41  2.24 0.025 0.56
6:152546094:G:A MED12mut- count NB  0.19 0.08  2.24 0.025 0.56
11:107999907:C:G Age at hysterectomy Linear 3.00 1.34 2.24 0.026 0.56
13:40723944:G:A MED12mut + count NB 0.36 0.17 2.17 0.030 0.56
22:40669648:A:G MED12mut + count NB 0.19 0.09 2.15 0.031 0.56
5:1286516:C:A MED12mut + count NB 0.17 0.08 2.15 0.031 0.56
22:40669648:A:G Age at hysterectomy Linear 1.36 0.63 2.16 0.032 0.56
1:22450487:C:T Age at hysterectomy Linear  1.48 0.72  2.05 0.041 0.65
16:51481596:G:A log(somatic AI basepairs) Linear 0.17 0.08 2.02 0.044 0.65
5:1288547:T:C Age at hysterectomy Linear 1.32 0.66 2.00 0.046 0.65
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Appendix 1—table 6. Summary of all the association tests for GRS. All GRS related tests from
the main text. The notation of MED12mut + and MED12mut- refer to the numbers of MED12-
mutation-positive and -negative tumors, respectively. The tests include Wilcoxon rank-sum and
models for linear and negative binomial (NB) regression (variable ~GRS). The P values were
adjusted for FWER with the Holm-Bonferroni method (Q). Significant associations (Q < 0.05) are
shown bolded. Note that population association tests include only the female controls.









Helsinki UL phenotype Rank-sum
(one-tailed)




NFBC UL phenotype Rank-sum
(one-tailed)




Helsinki Total number of
ULs
NB 457 - 1.25 0.00105 0.0032
Stage
2
Helsinki Age at hyster-
ectomy















Rank-sum 334 123 - 5.3e-04 0.0026
Stage
2
Helsinki All MED12mut+ Rank-sum 221 123 - 7.9e-04 0.0032
Stage
2
African # UL phenotype Rank-sum
(one-tailed)




Caribbean# UL phenotype Rank-sum
(one-tailed)




Irish # UL phenotype Rank-sum
(one-tailed)




Indian # UL phenotype Rank-sum
(one-tailed)







647 8982 - 6.9e-09 8.3e-
08
*Based either on stage 1 (UKBB GWAS) or stage 2 (meta-analysis of UKBB and Helsinki)
# An independent subset of UKBB data (stratified based on self-reported UKBB annotation).
DOI: https://doi.org/10.7554/eLife.37110.022
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Appendix 1—table 8. eQTLs in tumor and normal tissue. Here, B is the effect allele. All local
permutation p<0.05 are shown. Full table of eQTLs is given in Supplementary file 4.







ENSG00000269889.1 82 rs67795055 42457 9.10E-05 4.03E-04 0.224
T RUFY3 ENSG00000018189.8 8 rs7660770  972945 7.84E-04 6.68E-04 0.370
T TRIP13 ENSG00000071539.9 22 rs2736099 394581 1.63E-04 2.27E-03 1
N RN7SL832P ENSG00000243819.3 28 rs7570979 886958 4.06E-04 2.75E-03 1
N LNX1 ENSG00000072201.9 25 rs62323674 212300 7.12E-04 3.22E-03 1
N RP11-
849F2.8
ENSG00000269928.1 5 rs143094271  665038 2.43E-03 4.00E-03 1
T MIR5006 ENSG00000264190.1 158 rs9549254  907660 6.10E-04 4.42E-03 1
N RP11-
423H2.3
ENSG00000249684.1 50 rs183686  883235 3.36E-03 5.55E-03 1
N SLC7A3 ENSG00000165349.7 148 rs4360450 965 6.75E-04 7.38E-03 1
T ALPL ENSG00000162551.9 52 . 521370 8.48E-04 7.59E-03 1
N PRRG4 ENSG00000135378.3 167 rs11031737  478718 3.99E-04 8.59E-03 1
N RP11-
791G15.2
ENSG00000272275.1 28 rs6432220 802714 1.24E-03 8.81E-03 1
T ZDHHC11B ENSG00000206077.6 22 rs2736099 576864 9.74E-04 1.02E-02 1
T ACAP1 ENSG00000072818.7 5 rs78378222 331903 4.83E-03 1.04E-02 1
N HNRNPA1P48 ENSG00000224578.3 20 rs55881068  212266 4.97E-03 1.12E-02 1
T WNT4 ENSG00000162552.10 52 rs12042083 28933 1.30E-03 1.16E-02 1
T LRRIQ4 ENSG00000188306.6 82 rs13074500 25860 2.96E-03 1.20E-02 1
T TEX11 ENSG00000120498.9 148 rs11795627 208650 1.30E-03 1.23E-02 1
T AC011994.1 ENSG00000265583.1 28 rs11685032  73236 1.84E-03 1.32E-02 1
T FRMD7 ENSG00000165694.5 215 rs5933158 367012 8.40E-04 1.33E-02 1
N TRAPPC1 ENSG00000170043.7 5 rs138420351  133601 7.23E-03 1.44E-02 1
T RP11-
423H2.1
ENSG00000170089.11 72 rs353496  806511 9.37E-03 1.51E-02 1
N SDHAP3 ENSG00000185986.10 22 rs11742908  297655 1.42E-03 1.58E-02 1
T CDC42-IT1 ENSG00000230068.2 52 rs10917167 118400 2.10E-03 1.80E-02 1
N RP11-
362K14.6
ENSG00000270096.1 82 rs12638862  35245 4.49E-03 1.96E-02 1
T TNRC6B ENSG00000100354.16 32 rs12484951 262253 8.29E-03 1.97E-02 1
N DNAH2 ENSG00000183914.10 5 rs143094271  157571 9.73E-03 1.98E-02 1
N SALL1 ENSG00000103449.7 20 rs12933686 308913 9.53E-03 2.13E-02 1
T XXyac-
YRM2039.2
ENSG00000181404.13 71 rs138821078 659705 1.69E-03 2.22E-02 1
N ITPRIP ENSG00000148841.11 8 rs9419958  395949 1.43E-02 2.39E-02 1
T RNASEK-
C17orf49
ENSG00000161939.14 5 . 501685 1.19E-02 2.43E-02 1
T UQCRFS1P1 ENSG00000226085.2 32 rs1807579 256926 1.06E-02 2.44E-02 1
T FOXO1 ENSG00000150907.6 166 rs9549260 124299 2.94E-03 2.61E-02 1
T NDUFS6 ENSG00000145494.7 22 rs7734992  521387 2.81E-03 2.82E-02 1
T RP11-
259O2.3
ENSG00000249731.1 22 rs7710703  680704 2.89E-03 2.84E-02 1
T CDC42 ENSG00000070831.11 52 rs41307810  25076 3.35E-03 2.91E-02 1
Appendix 1—table 8 continued on next page
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Appendix 1—table 8 continued







ENSG00000227064.1 215 rs3764771  830073 2.03E-03 2.97E-02 1
T RP11-
362K14.7
ENSG00000270135.1 82 rs67795055 18611 7.45E-03 3.07E-02 1
N AMIGO2 ENSG00000139211.5 155 rs9706162  606808 6.28E-03 3.08E-02 1
T LPIN1 ENSG00000134324.7 28 rs11685032  143427 5.06E-03 3.33E-02 1
T MBNL3 ENSG00000076770.10 215 rs1263155 190718 2.55E-03 3.37E-02 1
N TOX3 ENSG00000103460.12 5 rs12325192  983789 3.24E-02 3.38E-02 1
N DANCR ENSG00000226950.2 23 rs62325482 885823 8.24E-03 3.54E-02 1
T DMRT1 ENSG00000137090.7 71 rs12004436  158261 3.09E-03 3.64E-02 1
N NT5C2 ENSG00000076685.14 8 rs1265164 828913 2.05E-02 3.75E-02 1
T TMEM256-
PLSCR3
ENSG00000187838.12 5 rs138420351 407016 1.77E-02 3.81E-02 1
T RP11-
401P9.4
ENSG00000261685.2 20 rs12933686 799079 1.64E-02 3.84E-02 1
N CTC1 ENSG00000178971.9 5 rs143094271  667090 1.89E-02 4.03E-02 1
N SULT1B1 ENSG00000173597.4 19 rs13133166 13318 1.49E-02 4.04E-02 1
N TNK1 ENSG00000174292.8 5 rs143094271 179248 2.24E-02 4.21E-02 1
T SOX15 ENSG00000129194.3 5 rs138420351 208566 2.02E-02 4.30E-02 1
T UGT2A1 ENSG00000173610.7 19 rs1587766 112959 2.06E-02 4.31E-02 1
T RP4-
607I7.1
ENSG00000255521.1 34 rs2553783  82085 2.66E-02 4.41E-02 1
N SENP3 ENSG00000161956.8 5 rs78378222 106559 2.19E-02 4.45E-02 1
N KDM6B ENSG00000132510.6 5 rs143094271  280121 2.16E-02 4.54E-02 1
T SKIL ENSG00000136603.9 82 rs34194057  525916 1.13E-02 4.63E-02 1
T EPHB2 ENSG00000133216.12 52 .  680104 6.04E-03 4.97E-02 1
DOI: https://doi.org/10.7554/eLife.37110.024
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Appendix 1—table 10. Replication of previously suggested UL predisposition loci. For study
details, see the literature references in the main text. The population, locus, gene and risk allele
(RA) information were collected from the original studies. The associations, P (UKBB) column,
were taken from the UKBB summary statistics for 15,453 UL cases. The bolded values pass
FWER (Bonferroni for seven independent loci; p<0.05/7).
Study Population Locus
Suggested
gene SNP RA Method
P
(UKBB)





22q13.1 TNRC6B rs12484776 G GWAS 1.0E-10





11p15.5 BET1L rs2280543 G GWAS 2.2E-08
Zhang et al. African Ameri-
cans
1q42.2 PCNXL2 rs7546784 - Admixture 3.6E-02
Zhang et al. African Ameri-
cans
2q32.2 PMS1 rs256552 - Admixture 1.8E-01
Cha et al. Japanese 10q24.33 SLK rs7913069 A GWAS 3.4E-01
Hellwege
et al.
African American 22q13.1 CYTH4 rs5995416 C GWAS 5.3E-01
Hellwege
et al.
African American 22q13.1 CYTH4 rs739187 C GWAS 6.2E-01
Hellwege
et al.
African American 22q13.1 CYTH4 rs713939 C GWAS 8.0E-01
Hellwege
et al.
African American 22q13.1 CYTH4 rs4821628 G GWAS 8.1E-01





Appendix 1—table 11. GWAS catalog and references to earlier literature on GRS SNPs. The
GRS SNPs rs10936600, rs11674184, rs2235529, rs2736100, rs2853676, rs72709458 and
rs78378222 were found in the GWAS catalog (version 1.0.1; www.ebi.ac.uk/gwas). The numbers






































































Appendix 1—table 11 continued on next page
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Appendix 1—table 11 continued
Pubmed Date Journal
Gene
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Appendix 1—table 11 continued
Pubmed Date Journal
Gene
symbol Risk allele AF OR P
27863252 2016-
11-17
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Appendix 1—figure 1. Structure of UL predisposition loci. The lead SNPs from stage one and
their genomic context. The LD estimates (r2) were taken from UK10k ALSPAC. Associations
are based on the UKBB cohort. Gene symbols and ENCODE tracks (details in Supplementary
Välimäki et al. eLife 2018;7:e37110. DOI: https://doi.org/10.7554/eLife.37110 41 of 50
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Methods) are shown for reference; coordinates follow hg19. See main text Table 1 for more
information. In total 22 figures, ordered by genomic position.
DOI: https://doi.org/10.7554/eLife.37110.028
Appendix 1—figure 2. Clinical background information for the Helsinki cohort patients. (A,)
the number of ULs per patient (n = 457). (B), patient’s age at hysterectomy (n = 392). (C),
parity (n = 367). (D), body mass index (BMI; n = 366). (E), menopause status (n = 367).
DOI: https://doi.org/10.7554/eLife.37110.029
Appendix 1—figure 3. MED12 mutation status distributions for the Helsinki cohort patients.
On left, mutation-positive tumors per patient (n = 457), and on right, mutation-negative
tumors per patient (n = 457).
DOI: https://doi.org/10.7554/eLife.37110.030
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Appendix 1—figure 4. Genetic separation between the self-reported ancestries in UK Bio-
bank. Principal components (PC) analysis of ancestry informative markers. In total 1396
autosomal, ancestry informative SNPs were used and the resulting first two PCs are shown:
top-left plot shows all 23,266 samples colored according to their self-reported ancestry. The
subsequent plots show the same data divided by the self-reported ancestry. Bottom-left plot
displays the variance explained by the first ten PCs. Bottom-right violin plot displays the
distribution of the first principal component for cases (n = 2,212) and controls (n = 21,054).
The phenotype is more prevalent in individuals with increased African ancestry
(p<2.2  10 16; Wilcoxon rank sum W = 3  107).
DOI: https://doi.org/10.7554/eLife.37110.031
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Appendix 1—figure 5. Association between GRS and phenotype. One somatic phenotype
(MED12 mutation status) and six independent case-control replication cohorts. On left,
density plots (bandwidth = 0.2) for each phenotype. X-axis gives GRS values scaled to unit
variance with respect to the controls. Dashed lines denote the mean GRS for cases and
controls. Associations (P) and test statistics (W) are from Wilcoxon rank-sum tests. C-scores,
Nagelkerke’s R2 (pseudo R2) and Receiver operating characteristic (ROC; on right) are from a
logistic regression model. Positive predictive values (PPV) were computed from the highest
GRS quartile, and odds ratios (OR and 95% CI) from the top and bottom GRS quartiles.
DOI: https://doi.org/10.7554/eLife.37110.032
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Appendix 1—figure 6. Genomic risk scores in gnomAD populations. Population-specific
genomic risk scores (GRS) as seen based on gnomAD allele frequencies. Y-axis shows the
cumulative effect of each of the 57 GRS SNPs; the X-axis is ordered by risk allele frequency.
The population names displayed here follow the naming convention of the gnomAD
database.
DOI: https://doi.org/10.7554/eLife.37110.033
Appendix 1—figure 7. Association between GRS and number of ULs per patient. The
Välimäki et al. eLife 2018;7:e37110. DOI: https://doi.org/10.7554/eLife.37110 45 of 50
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numbers are based on the Helsinki cohort data of 457 patients with all distinct tumors of 1
cm diameter harvested at hysterectomy; details on sample collection are given in
Supplementary Methods. A, summary of the model. B, diagnostic plots for the model.
DOI: https://doi.org/10.7554/eLife.37110.034
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Appendix 1—figure 8. Association between GRS and MED12 mutations. The numbers are
based on the Helsinki cohort data (457 patients). (A) summary of the negative binomial
model for MED12-mutation-positive tumor counts. (B) diagnostic plots for the negative
binomial model. (C, D) similar model for the MED12-mutation-negative tumor counts.
Välimäki et al. eLife 2018;7:e37110. DOI: https://doi.org/10.7554/eLife.37110 47 of 50
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DOI: https://doi.org/10.7554/eLife.37110.035
Appendix 1—figure 9. meQTLs at TERT region. Hi-C, TADs and CpG methylation around
rs2736100 with an 1Mbp flank. The needle plot shows the meQTL associations (dashed lines
at 10% FDR; green line denotes the two SNPs; gray ticks denote all CpGs tested; blue
needle for positive coefficient, red for negative coefficient) for tumors (above x-axis; nAA = 8,
nAB = 32, nBB = 16) and normals (below x-axis; nAA = 5, nAB = 22, nBB = 7). The only
significant meQTLs were seen around TERT.
DOI: https://doi.org/10.7554/eLife.37110.036
Appendix 1—figure 10. Overview of the CpG methylation around TERT in tumor tissue.
There are several CpGs in TERT whose methylation level is associated with rs2736100
genotype (nominal p<0.05). Some of them are also detected in normal tissue (Appendix 1—
Table 9). Hypomethylation refers to decreased methylation in BB vs. AA genotype and
hypermethylation the opposite.
DOI: https://doi.org/10.7554/eLife.37110.037
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Appendix 1—figure 11. MED12 expression. Linear model. Here, A is the risk allele. Beta
0.247 ± 0.177.
DOI: https://doi.org/10.7554/eLife.37110.038
Appendix 1—figure 12. Telomere lengths in tumors and normals. Here A denotes the risk
allele (see Appendix 1—Table 1 for the allele information). In tumors, shorter telomere
length is significantly associated with the risk allele at 5p15.33 (rs2736100) (Kruskal-Wallis
test).
DOI: https://doi.org/10.7554/eLife.37110.039
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Appendix 1—figure 13. The association between risk allele count and telomere length On
X-axis, total number of risk alleles at TERT (rs72709458, rs2736100, rs2853676), TERC
(rs10936600) and OBFC1 (rs1265164). On Y-axis, estimated telomere length. Linear regression
model p=0.055; 95% CI  408.511 – 4.704 per one risk allele.
DOI: https://doi.org/10.7554/eLife.37110.040
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